Given the expression of the six genes shown to be associated with endocrine therapy resistance and MEK inhibitor sensitivity in cancer cell lines (Fig. 5d), we further confirmed the expression fold changes in the tumor samples with high EERES comparing to low EERES with R package DESeq2 for breast, ovarian, endometrial, and cervical cancers. This evidence concerns the gene MAP2K7 and neoplasm.